SCHEMBL1944247

SCHEMBL1944247

CC(C)Oc1ccc(Nc2ncc(F)c(NC3CC(C)(C)N(C)C(C)(C)C3)n2)cc1-n1nnn(C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 3/20 0.51
SYK P43405 7/20 0.40
EGFR P00533 5/20 0.38
CDK2 P24941 2/20 0.38
CCNA2 P20248 1/20 0.38
PLK1 P53350 1/20 0.38
CCNA1 P78396 1/20 0.38
BCL6 P41182 2/20 0.37
CHEK1 O14757 2/20 0.36
FLT3 P36888 2/20 0.36
ITK Q08881 3/20 0.36
AURKA O14965 2/20 0.36
AURKB Q96GD4 2/20 0.36
ALK Q9UM73 2/20 0.36
KDR P35968 2/20 0.35
BTK Q06187 2/20 0.35
CDC7 O00311 1/20 0.35
PLK4 O00444 1/20 0.35
DCLK1 O15075 1/20 0.35
PDPK1 O15530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945929 0.92 PRKCQ (0.42) PRKCQSYKEGFRBCL6CHEK1
SCHEMBL1944983 0.89 PRKCQ (0.56) PRKCQSYKEGFRCDK2CHEK1
SCHEMBL1944038 0.88 PRKCQ (0.49) PRKCQSYKEGFRCDK2CCNA2
SCHEMBL1944254 0.87 PRKCQ (0.49) PRKCQSYKEGFRCDK2CCNA2
SCHEMBL1942649 0.87 PRKCQ (0.54) PRKCQSYKEGFRCDK2CHEK1
SCHEMBL1943354 0.87 PRKCQ (0.52) PRKCQSYKEGFRCDK2BCL6
SCHEMBL1943697 0.86 PRKCQ (0.48) PRKCQSYKEGFRBCL6ITK
SCHEMBL1742552 0.86 PRKCQ (0.53) PRKCQSYKEGFRCDK2CCNA2
SCHEMBL1943301 0.85 PRKCQ (0.48) PRKCQSYKCDK2CCNA2PLK1
SCHEMBL1945345 0.85 PRKCQ (0.51) PRKCQSYKEGFRCDK2BCL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507227-B1 TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2014-10-08 EP claimed
WO-2011068898-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2011-06-09 WO claimed
US-20110130415-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. 2011-06-02 US claimed
US-9732070-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-20170152246-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2017-06-01 US disclosed
EP-2507227-B1 TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2014-10-08 EP disclosed
EP-2507227-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF Rigel Pharmaceuticals, Inc. (US) 2012-10-10 EP disclosed
WO-2011068898-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed
US-20110130415-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130415-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB PRKCQ 5/4885SYK 600/4885EGFR 2299/4885
US-20170152246-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB PRKCQ 5/4885SYK 600/4885EGFR 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.